PDE5A and renovascular hypertension: According to our concept, low doses of PDE5 inhibitors reported to preferentially inhibit the cGMP-bound, activated state of the enzyme, appear to be indicated as a possible rational pharmacological intervention in the treatment of renovascular hypertension.